Engineered Antibody Class Switch Recombination
Inventors: Taek-Chin Cheong, Roberto Chiarle
Invention Types: Therapeutics, Research Tool
Research Areas: Immunology
Keywords: AntibodyFor More Information Contact: Caron, Connie
Class switch recombination (CSR) occurs during the normal maturation of B-cells. The initial step of CSR is the binding of an antigen to the B-cell surface-expressed immunoglobulin (Ig) H. Provided that the proper cytokines are present, antigen binding sets off a sequence of biological events that eventually lead to different mature B-cell populations each displaying or secreting antibodies of different classes. These classes reflect changes in the constant region of the antibody while the variable (antigen binding) region remains unaltered. The different classes of antibodies elicit differential interactions between host factors and the variable constant regions permitting the immune system to respond to the same antigen through distinct mechanisms. However, inducing CSR in vitro is time consuming, sometimes requiring multiple sequential B-cell cultures in the presence of different cytokines.
Roberto Chiarle’s group at Boston Children’s Hospital has developed an alternative approach to inducing CSR. Instead of the traditional cytokine B-cell culture approach, Chiarle’s group has employed CRISPR/Cas9 gene editing technology and guide RNA molecules designed to induce specific class changes. These class changes can be induced in both naïve B-cells and hybridoma without the need for time-consuming and expensive cell cultures in a sequence of conditions. In addition to the CSR work, the researchers also successfully induced Fab fragment production in B-cells and hybridoma. Together, this set of methods allows straightforward, one-step approaches to manipulate antibodies and their classes for therapeutic and research purposes. The techniques and reagents developed by Chiarle’s group are ideally positioned to deliver significant gains in the workflow efficiency of antibody providers.
• Production of antibodies with identical epitopes with any desired constant region or without a constant region.
• More time and cost efficient than traditional cytokine approaches to inducing CSR.
• Fab fragment production from the same hybridoma/B-cell line as the antibody.
Non-exclusive license, Exclusive license
IPStatus: Pat. Pend.